Jonathan A Bernstein, EAACI 2022: Findings from the Phase 2b Extension Study of Ligelizumab in Chronic Spontaneous Urticaria
Ligelizumab is a monoclonal anti-immunoglobulin (Ig) E antibody that has been investigated in the treatment of chronic spontaneous urticaria. touchIMMUNOLOGY were delighted to speak with Prof. Jonathan A Bernstein (University of Cincinnati; Bernstein Allergy Group & Bernstein Clinical Research Center, Cincinnati, OH, USA) around the aims, design and findings from the phase 2b extension study and the future of ligelizumab after failing to show superiority to omalizumab in this indication.
The abstract ‘Long term control of urticaria disease activity with ligelizumab in patients with chronic spontaneous urticaria: data from the Phase 2b extension study.‘ was presented at EAACI 2022, 1-3 July, 2022.
- Could you describe the current standard of care for chronic spontaneous urticaria (CSU)? (0:21)
- What is ligelizumab and what was the rationale for its use in CSU? (3:18)
- Could you describe the aims, design and inclusion criteria of the phase 2b extension study? (4:17)
- What were the findings of the study and were these consistent with the core study? (5:26)
- Given the failure of ligelizumab to demonstrate superiority vs omalizumab in the PEARL 1 and PEARL 2 Phase III studies, will the clinical development of ligelizumab continue in this indication? (6:39)
Disclosures: Jonathan Bernstein discloses consulting for Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; receiving grant/ research support from Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; serving on advisory boards for Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; receiving honoraria from Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; and participating in speaker’s bureaus for Genentech, Novartis, Astra Zeneca and Sanofi Regeneron.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EAACI Hybrid Congress 2022.
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!